|
Inovio Pharmaceuticals, Inc. (INO) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Inovio Pharmaceuticals, Inc. (INO) Bundle
Explore the financial outlook of Inovio Pharmaceuticals, Inc. (INO) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to determine the intrinsic value of Inovio Pharmaceuticals, Inc. (INO) and refine your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.1 | 7.4 | 1.8 | 10.3 | .8 | .9 | .9 | .9 | .9 | 1.0 |
| Revenue Growth, % | 0 | 80.24 | -76.05 | 478.23 | -91.89 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 |
| EBITDA | -107.3 | -149.6 | -296.6 | -270.9 | -130.4 | -.9 | -.9 | -.9 | -.9 | -1.0 |
| EBITDA, % | -2610.55 | -2018.02 | -16709.72 | -2639.8 | -15671.81 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 5.5 | 4.6 | 4.7 | 5.5 | 3.5 | .7 | .7 | .8 | .8 | .8 |
| Depreciation, % | 134.16 | 62.44 | 266.56 | 53.56 | 421.09 | 83.2 | 83.2 | 83.2 | 83.2 | 83.2 |
| EBIT | -112.9 | -154.2 | -301.3 | -276.4 | -133.9 | -.9 | -.9 | -.9 | -.9 | -1.0 |
| EBIT, % | -2744.71 | -2080.47 | -16976.28 | -2693.35 | -16092.9 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 89.5 | 411.6 | 401.3 | 253.0 | 145.3 | .9 | .9 | .9 | .9 | 1.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.0 | 19.1 | 8.0 | 11.7 | 2.4 | .8 | .8 | .8 | .8 | .9 |
| Account Receivables, % | 49.42 | 257.23 | 452.57 | 114.38 | 289.09 | 89.88 | 89.88 | 89.88 | 89.88 | 89.88 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 7.6 | 1.5 | 28.0 | 21.1 | 4.6 | .7 | .7 | .8 | .8 | .8 |
| Accounts Payable, % | 186.02 | 19.81 | 1576.15 | 205.44 | 558.69 | 83.96 | 83.96 | 83.96 | 83.96 | 83.96 |
| Capital Expenditure | -1.0 | -1.5 | -1.2 | -1.0 | -.3 | -.3 | -.3 | -.3 | -.3 | -.3 |
| Capital Expenditure, % | -24.03 | -20.52 | -69.36 | -9.44 | -38.57 | -32.38 | -32.38 | -32.38 | -32.38 | -32.38 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -112.6 | -203.6 | -303.4 | -286.4 | -133.9 | -.9 | -.9 | -.9 | -.9 | -1.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -102.5 | -223.7 | -262.4 | -292.4 | -137.8 | -2.7 | -.4 | -.4 | -.5 | -.5 |
| WACC, % | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -10 | |||||||||
| Present Terminal Value | -7 | |||||||||
| Enterprise Value | -11 | |||||||||
| Net Debt | 16 | |||||||||
| Equity Value | -27 | |||||||||
| Diluted Shares Outstanding, MM | 22 | |||||||||
| Equity Value Per Share | -1.23 |
What You Will Get
- Real Inovio Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Inovio Pharmaceuticals, Inc. (INO).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Inovio.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Inovio’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Inovio Pharmaceuticals, Inc. (INO).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Inovio.
Key Features
- Customizable Research Parameters: Adjust vital inputs such as clinical trial success rates, R&D expenditures, and market penetration.
- Instant Valuation Metrics: Quickly computes intrinsic value, NPV, and other critical financial indicators.
- High-Precision Analytics: Leverages Inovio’s actual financial data for dependable valuation results.
- Effortless Scenario Testing: Evaluate various hypotheses and analyze results with ease.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- 1. Access the Template: Download and open the Excel file containing Inovio Pharmaceuticals, Inc.'s (INO) financial data.
- 2. Modify Assumptions: Adjust key parameters such as growth projections, WACC, and capital expenditures.
- 3. Analyze Results Quickly: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Evaluate Scenarios: Test various forecasts to explore different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to enhance your decision-making process.
Why Choose the Inovio Calculator?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses tailored for Inovio Pharmaceuticals (INO).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Inovio’s intrinsic value and Net Present Value.
- Preloaded Data: Includes historical and forecasted data for precise initial assessments.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on Inovio Pharmaceuticals (INO).
Who Should Use This Product?
- Investors: Evaluate Inovio Pharmaceuticals’ valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess financial projections.
- Startup Founders: Understand how biotechnology firms like Inovio Pharmaceuticals are appraised.
- Consultants: Provide expert valuation analyses and reports for clients in the healthcare sector.
- Students and Educators: Utilize real-time data to learn and teach valuation strategies in the biotech field.
What the Template Contains
- Pre-Filled DCF Model: Inovio Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Inovio Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.